Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...
Herpes Zoster (Shingles) Global Clinical Trials Review 2024: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type And End-Point Status
( MENAFN - GlobeNewsWire - Nasdaq) Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Herpes Zoster (Shingles) - Global Clinical Trials Review, 2024" clinical trials has been added to ...
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than $100 million in 2026 growing to over $175 ...